Alex Biese

Besponsa provides another — and potentially more effective — option outside of traditional chemotherapy for pediatric patients with relapsed or refractory B-ALL.

Experts from City of Hope explain the importance of symptom management and care planning during cancer.

Across disease stages, Black patients with renal cell carcinoma experience worse survival outcomes than White patients, research has shown.

Dendritic cell maturation agent plinabulin, immunotherapy and chemotherapy are being studied in first-line extensive-stage small cell lung cancer.

Patients with inoperable kidney cancer saw significant results in local control and cancer-specific survival with stereotactic ablative body radiotherapy.

The investigational drug LSTA1 is being explored for the treatment of osteosarcoma, which starts in the bones and accounts for 2% of childhood cancers.

Subcutaneous administration of Opdivo, could increase efficiency and reduce wait times for patients, as one expert explains to CURE®.

As part of its Speaking Out video series, CURE® spoke with Lillian Dugan of the Dear Jack Foundation about the needs of caregivers for adolescent and young adult patients with cancer.

As part of its Speaking Out video series, CURE® spoke with Lillian Dugan of the Dear Jack Foundation about the issues faced by adolescent and young adult patients with cancer as they age into adult care.

As part of its Speaking Out video series, CURE® spoke with Lillian Dugan of the Dear Jack Foundation about how a cancer diagnosis ‘adds a new identity’ for adolescent and young adult patients.

As part of its Speaking Out video series, CURE® spoke with Lillian Dugan of the Dear Jack Foundation about the power of mindfulness practices such as yoga and meditation.

As part of its Speaking Out video series, CURE® spoke with Lillian Dugan of the Dear Jack Foundation about the current landscape of research for adolescent and young adult patients with cancer.

One expert explains how caregivers are a vital part of the care team during a clinical trial.

Researchers have determined distinguishing characteristics of TFE3-rearranged renal cell carcinoma.

The Food and Drug Administration granted an accelerated approval to Iclusig, described as the new “standard of care” for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

During the Miami Breast Cancer Conference and Educated Patient® Breast Cancer Summit, one expert stressed the importance of genetic testing for BRCA mutations.

The director of programs for the Dear Jack Foundation explains issues young patients with cancer may face into adulthood.

Breyanzi has been approved by the FDA for some previously treated patients with CLL or SLL — marking the first CAR-T cell therapy approved for this patient population.

With cybersecurity a pressing concern for patients, CURE® spoke with experts about protective measures they can take to protect themselves online.

A patient with breast cancer shares skills she’s learned from the Look Good Feel Better program at the Miami Breast Cancer Conference and Educated Patient® Breast Cancer Summit.

As part of its Speaking Out video series, CURE® spoke with Lisa Carter-Bawa of Hackensack Meridian Health about the role nurses play in helping patients manage treatment side effects.

As part of its Speaking Out video series, CURE® spoke with Upal Basu Roy of LUNGevity about recently approved treatments for lung cancer and what is on the horizon.

As part of its Speaking Out video series, CURE® spoke with Amy C. Moore of LUNGevity about the chemotherapy shortage and its impact on patients with lung cancer.

As part of its Speaking Out video series, CURE® spoke with Amy C. Moore of Lungevity about advancements in treatments for small cell lung cancer.

As part of its Speaking Out video series, CURE® spoke with Brandon Leonard of the LUNGevity Foundation about the role legislation can play in a patient’s cancer journey.

With cyberattacks on medical institutions on the rise, CURE® spoke with an online security expert about steps patients should take if they believe their data has been exposed.

Some patients are forced to deal with “infuriating” attempts at exploitation while navigating their disease.

Artificial intelligence platform ChatGPT is capable of providing “widely understandable and accessible” answers about kidney cancer, but experts express caution.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

The Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic bladder cancer, the agency has announced.